Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analystJP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high Share XModerna’s $37B market cap is too high, despite COVID-19 vaccine; analysthttps://pharmaphorum.com/news/modernas-37b-market-cap-is-too-high-despite-covid-19-vaccine-analyst/
Talks from the MHRA, Innovate UK, Plasticell and moreCell and Gene Therapy Share XTalks from the MHRA, Innovate UK, Plasticell and morehttps://pharmaphorum.com/partner-content/talks-from-the-mhra-innovate-uk-plasticell-and-more/